Senhwa Biosciences CX-5461 Secures NCI Support to Advance into MYC-Driven Lymphoma, Driving Cross-Cancer and Global Licensing Value ...Middle East

TAIPEI and SAN DIEGO, Sept. 5, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) has granted IND clearance for its innovative drug candidate Pidnarulex(CX-5461) ina Phase...

Hence then, the article about senhwa biosciences cx 5461 secures nci support to advance into myc driven lymphoma driving cross cancer and global licensing value was published today ( Friday 05/09/2025 - 11:47 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Senhwa Biosciences CX-5461 Secures NCI Support to Advance into MYC-Driven Lymphoma, Driving Cross-Cancer and Global Licensing Value )

Also on site :

• Tokyo's Yamanote Line suspended due to power outage
• 2000s Heavy Metal Band Shares Exciting Music Festival News
• Tokyo's Yamanote loop line trains out of service due to power outage